Finding 1166792 (2024-010)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2024
Accepted
2025-12-29

AI Summary

  • Core Issue: The Organization miscalculated the indirect cost rate by not using the approved rates or cost base for administrative expenses.
  • Impacted Requirements: This violates the Health and Human Services Grant Policy, which mandates using negotiated rates for indirect cost calculations.
  • Recommended Follow-Up: Re-establish internal controls to monitor allowable expenditures and ensure proper reconciliation of qualifying costs with cash draws.

Finding Text

Finding: Incorrect calculation of indirect cost rate. Criteria: Allowable Costs/ Cost Principles (Non-profit Organization) Per the Health and Human Services Grant Policy Document: "For all recipients […] the negotiated rate in effect at the beginning of each budget period will be used as the basis for determining indirect costs for that budget period. Per the contracts and final rate notifications referenced below, direct salaries and wages excluding fringe benefits are the base for indirect expense allocations. Condition and Context, and Cause: During our audit, we recalculated the indirect cost allocations and noted the Organization was not utilizing the approved rates or cost base in the administrative expense allocation. Amounts were considered unallowable if expenditures exceeded allowable salary expense multiplied by the approved cost rates in the applicable budget periods. See discussion above at 2024-006 additional context/cause. Result: Amounts identified as unallowable costs per the compliance guidance have been included in the contract liability as disclosed in Note 12. See the Summary of Unallowable Costs and Questioned Costs tables for detail on page 56. Recommendation: The auditors recommend the Organization re-implement internal controls to track allowable expenditures and reconcile qualifying costs with cash draws.

Corrective Action Plan

As discussed above Cayuga Centers has engaged grants management advisors who will assist in evaluating this specific finding. To the extent that the finding merely asserts that indirect cost bases were improperly calculated in prior periods, please see Cayuga Centers’ response and actions steps with respect to findings 2024-001 through 006. If, upon full evaluation, Cayuga Centers concurs that indirect costs were improperly charged, it will address the matter with its primary funding agency as part of broader resolution of any unallowable costs.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1166741 2024-003
    Material Weakness Repeat
  • 1166742 2024-004
    Material Weakness Repeat
  • 1166743 2024-005
    Material Weakness Repeat
  • 1166744 2024-006
    Material Weakness Repeat
  • 1166745 2024-007
    Material Weakness Repeat
  • 1166746 2024-008
    Material Weakness Repeat
  • 1166747 2024-009
    Material Weakness Repeat
  • 1166748 2024-010
    Material Weakness Repeat
  • 1166749 2024-011
    Material Weakness Repeat
  • 1166750 2024-012
    Material Weakness Repeat
  • 1166751 2024-013
    Material Weakness Repeat
  • 1166752 2024-003
    Material Weakness Repeat
  • 1166753 2024-004
    Material Weakness Repeat
  • 1166754 2024-005
    Material Weakness Repeat
  • 1166755 2024-006
    Material Weakness Repeat
  • 1166756 2024-007
    Material Weakness Repeat
  • 1166757 2024-008
    Material Weakness Repeat
  • 1166758 2024-009
    Material Weakness Repeat
  • 1166759 2024-010
    Material Weakness Repeat
  • 1166760 2024-011
    Material Weakness Repeat
  • 1166761 2024-012
    Material Weakness Repeat
  • 1166762 2024-013
    Material Weakness Repeat
  • 1166763 2024-003
    Material Weakness Repeat
  • 1166764 2024-004
    Material Weakness Repeat
  • 1166765 2024-005
    Material Weakness Repeat
  • 1166766 2024-006
    Material Weakness Repeat
  • 1166767 2024-007
    Material Weakness Repeat
  • 1166768 2024-008
    Material Weakness Repeat
  • 1166769 2024-009
    Material Weakness Repeat
  • 1166770 2024-010
    Material Weakness Repeat
  • 1166771 2024-011
    Material Weakness Repeat
  • 1166772 2024-012
    Material Weakness Repeat
  • 1166773 2024-013
    Material Weakness Repeat
  • 1166774 2024-003
    Material Weakness Repeat
  • 1166775 2024-004
    Material Weakness Repeat
  • 1166776 2024-005
    Material Weakness Repeat
  • 1166777 2024-006
    Material Weakness Repeat
  • 1166778 2024-007
    Material Weakness Repeat
  • 1166779 2024-008
    Material Weakness Repeat
  • 1166780 2024-009
    Material Weakness Repeat
  • 1166781 2024-010
    Material Weakness Repeat
  • 1166782 2024-011
    Material Weakness Repeat
  • 1166783 2024-012
    Material Weakness Repeat
  • 1166784 2024-013
    Material Weakness Repeat
  • 1166785 2024-003
    Material Weakness Repeat
  • 1166786 2024-004
    Material Weakness Repeat
  • 1166787 2024-005
    Material Weakness Repeat
  • 1166788 2024-006
    Material Weakness Repeat
  • 1166789 2024-007
    Material Weakness Repeat
  • 1166790 2024-008
    Material Weakness Repeat
  • 1166791 2024-009
    Material Weakness Repeat
  • 1166793 2024-011
    Material Weakness Repeat
  • 1166794 2024-012
    Material Weakness Repeat
  • 1166795 2024-013
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.676 UNACCOMPANIED CHILDREN PROGRAM $5.28M
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $260,463